References
Allen DK. 1997. ‘The return of thalidomide: are we ready
to forget images like this and give the drug
another chance?’St. Louis Post-Dispatch: 28 Septem-
ber; 01B.
Allen DK, Bourne CJ, Holyoak JH (eds). 1979.Accident
Compensation after Pearson.Sweet & Maxwell:
London; 161, chapter 3.
Barker v. Lull Engineering.1978. 20 Cal. 3d 413, 573 p.
2d 443, 143 Cal. Rptr. 225.
Bernstein S. 1997. ‘Formed by thalidomide: mass torts
as a false cure for toxic exposure’.Columbia Law
Rev. 97 : 2153.
Bichler v. Ru Lilly & Co.1982. 79 App. Div. 2d 317, 436
N.Y.S. 2d 625 (App. Div. 1981); 55 N.Y. 2d 571, 450
N.Y.S. 2d 776, 436 N.E. 2d 182.
Brahams D. 1991. ‘Diethylstilbestrol: [sic] third-
generation injury claims’. Medico-Legal J. 59 :
126.
Buitendijk S. 1984. ‘DES – the time bomb drug’. In
Report of the 13th European Symposium on Clinical
Pharmacological Evaluation in Drug Control.
World Health Organization: Regional Office for
Europe, Copenhagen.
Burley D. 1986. ‘The decline and fall of thalidomide’.
InOrphan Diseases and Orphan Drugs, Scheinberg
IH (ed.). Manchester University Press (in association
with The Fulbright Commission): London.
Cook T, Doyle C, Jabbari D. 1991.Pharmaceuticals,
Biotechnology and the Law.Macmillan: Basing-
stoke; 364.
Crawford CL. 1994. ‘Use of thalidomide in leprosy.
Adverse Drug React. Toxicol. Rev. 13 : 177.
D’Arcy PF. 1994. ‘Thalidomide revisited. Thirteen
adverse drug reactions’.Toxicol. Rev. 13 : 65.
Enright v. Eli Lilly & Co.1991. 77 N.Y. 2d 377, 570
N.E. 2d 198 (1991).
European Federation of Pharmaceutical Industries and
Associations. 1999.Green Paper on Liability for
Defective Products.
Dukes G, Mildred M, Swartz B. 1998.Responsibility
for Drug-induced Injury a Reference Book for
Health Professions and Manufacturers.IOS Press:
Oxford.
Dutton DB. 1988.Worse than the Disease: Pitfalls of
Medical Progress. Cambridge University Press:
Cambridge; 87.
Dworkin R. 1979. ‘Pearson: implications for severely
handicapped children and products liability’. In
Accident Compensation After Pearson.Allen DK,
Bourne CJ, Holyoak JH (eds). Sweet & Maxwell:
London.
Epstein RA. 1995.Cases and Materials on Torts, 6th
edn. Little, Brown: Boston; 727–730.
Ferguson PR. 1992. ‘Pharmaceutical products
liability: 30 years of law reform?Juridical Rev. 3 :
226–239.
Ferguson PR. 1996.Drug Injuries and the Pursuit of
Compensation.Sweet & Maxwell: London.
Flaherty. 1984. ‘Last thalidomide suits settle to end
legal era’.Natl. Law J. 6 : 32.
Garbutt BJ, Hofmann ME. 2003. ‘Recent developments
in pharmaceutical products liability law: failure to
warn, the learned intermediary defense, and other
issues in the new millennium’.Food Drug Law J.
58 (2): 269–286.
Hamilton v. Fife Health Board.1993. 4 Med. L.R. 201;
1993 S.L.T. 624; 1993 S.C.L.R. 408.
Harris Interactive Inc. 1993.Pharmaceutical Liability
Study commissioned by the U.S. Chamber Institute
for Legal Reform, Washington, DC.
Heuston RFV, Buckley RA. 1992.Salmond & Heuston
on the Law of Torts, 20th edn. Sweet & Maxwell:
London; 310–312.
Hunter R. 1993. ‘Product liability: dangerous to devel-
opment’.Int. Corporate Law 27 : 27–28.
Hymowitz v. Eli Lilly & Co.1989. 73 N.Y. 2d 487, 539
N.E. 2d 1069, 541 N.Y.S 2d 941.
Jones MA. 1993.Textbook on Torts, 4th edn. Black-
stone: London; 302–313.
Lifton DE, Bufano MM. 2004. ‘A call for continued
state law tort reform’.Pharm. Med. Device Law
Bull.4(3).
McCartney TE, Rheingold PD. 1996. ‘From prescrip-
tion to over-the-counter: watered-down warnings’.
Trial 32 (34): 24.
Moore MJ, Viscusi WK. 2001.Product Liability Enter-
ing the Twenty-First Century.AEI-Brookings Joint
Center for Regulatory Studies: Washington, DC.
Moore TM, Cullen SA. 1999. ‘Impact of global phar-
maceutical regulations on US products liability
exposure’.Defense Counsel J. 66 (1): 101–108.
Mossialos E, Ranos C, Abel-Smith B. 1994. Cost
Containment, Pricing and Financing of Pharmaceu-
ticals in the European Community: The Policy-
Maker’s View.LSE Health and Pharmetrica: Athens;
18–19.
Nace BJ, Robb GC, Rogers JS,et al.1997. ‘Products
liability: tips and tactics’.Trial 33 (11): 38.
Pendell J. 2003.The Adverse Side Effects of Pharma-
ceutical Litigation.AEI-Brookings Joint Center for
Regulatory Studies: Washington, DC.616 CH47 PHARMACEUTICAL PRODUCT LIABILITY